A detailed history of Privium Fund Management B.V. transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 80,232 shares of AXSM stock, worth $7.5 Million. This represents 1.8% of its overall portfolio holdings.

Number of Shares
80,232
Previous 74,332 7.94%
Holding current value
$7.5 Million
Previous $5.98 Million 20.47%
% of portfolio
1.8%
Previous 1.69%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$78.93 - $95.84 $465,687 - $565,456
5,900 Added 7.94%
80,232 $7.21 Million
Q2 2024

Jul 31, 2024

SELL
$65.72 - $80.5 $506,044 - $619,850
-7,700 Reduced 9.39%
74,332 $5.98 Million
Q1 2024

Apr 30, 2024

BUY
$69.39 - $97.64 $693,900 - $976,400
10,000 Added 13.88%
82,032 $6.55 Million
Q2 2023

Jul 25, 2023

SELL
$58.41 - $90.35 $5.11 Million - $7.9 Million
-87,442 Reduced 54.83%
72,032 $5.18 Million
Q1 2023

May 03, 2023

BUY
$58.39 - $75.0 $9.31 Million - $12 Million
159,474 New
159,474 $9.84 Million

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $4.01B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Privium Fund Management B.V. Portfolio

Follow Privium Fund Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Privium Fund Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Privium Fund Management B.V. with notifications on news.